Vaxcyte Inc., a clinical-stage vaccine innovation company, has announced a new agreement with Thermo Fisher Scientific to expand domestic fill-finish manufacturing capacity for its broad-spectrum pneumococcal conjugate vaccine candidates. Under the agreement, Thermo Fisher will provide custom commercial fill-finish services at its Greenville, North Carolina facility. The initiative is part of Vaxcyte's long-term U.S. commercial supply strategy and represents up to $1 billion in manufacturing and related services. The expanded capacity is intended to support the future commercial manufacturing of Vaxcyte's vaccines and strengthen the company's domestic supply chain.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9537277-en) on September 30, 2025, and is solely responsible for the information contained therein.